Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tranexamic Acid · 1 trial · 2 indications
Mortality at 24 hours
Mortality at 48 hours
Mortality at 28 days
| Arm | Type | Description |
|---|---|---|
| Prehospital Tranexamic Acid | EXPERIMENTAL | 1 gram of Tranexamic Acid will be given during medical transport |
| Matched Controls | NO_INTERVENTION | Retrospective matched controls |
| Name | Type | Description |
|---|---|---|
| Tranexamic Acid | DRUG | 1 gram of prehospital Tranexamic Acid |
Inclusion Criteria: * Blunt or penetrating trauma with signs and symptoms of hemorrhagic shock * Systolic blood pressure less than 90 mmHg at scene of injury, during air and/or ground medical transport, or on arrival to designated trauma centers * Any sustained blunt or penetrating injury within 3 ...
Tranexamic Acid is used for hemorrhagic shock, a condition of severe blood loss that can occur after trauma injury. It is being studied as a treatment to help control bleeding in patients experiencing this life-threatening condition.
Tranexamic Acid is being developed by Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ARWR.
Tranexamic Acid is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 3 trial has been completed, but the drug remains under investigation for the treatment of hemorrhagic shock.
Tranexamic Acid has one completed Phase 3 clinical trial with the identifier NCT03469947, titled 'California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA'. This trial enrolled 200 participants with hemorrhagic shock and trauma injury.
Yes, Tranexamic Acid is a small molecule drug. It is being developed as a therapeutic agent for hemorrhagic shock and is administered to patients experiencing severe bleeding.